Flagship V VentureLabs Rx Fund, L.P.
CIK 0001724939 Name as filed on the most recent filing
Filed as Flagship V VentureLabs Rx Fund, L.P. (6)
17 transaction lines · from 6 filings · filed 2018-05-15 to 2023-06-08 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER Sana Biotechnology, Inc. 2 filings
- ISSUER Codiak BioSciences, Inc. 2 filings
- ISSUER Omega Therapeutics, Inc. 1 filings
- ISSUER Evelo Biosciences, Inc. 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2023-06-07 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 177,240 disposed | 6.24 | 1,105,924.43 | Form 4, filing 0000899243-23-014953 | |
| 2023-06-07 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 22,760 disposed | 6.24 | 142,015.57 | Form 4, filing 0000899243-23-014953 | |
| 2023-06-06 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 181,461 disposed | 6.31 | 1,144,311.21 | Form 4, filing 0000899243-23-014953 | |
| 2023-06-06 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 22,297 disposed | 6.31 | 140,607.11 | Form 4, filing 0000899243-23-014953 | |
| 2023-05-26 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 72,670 disposed | 6.23 | 452,479.76 | Form 4, filing 0000899243-23-013992 | |
| 2023-05-26 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 9,330 disposed | 6.23 | 58,093.24 | Form 4, filing 0000899243-23-013992 | |
| 2023-05-25 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 102,245 disposed | 6.35 | 649,480.69 | Form 4, filing 0000899243-23-013992 | |
| 2023-05-25 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 13,127 disposed | 6.35 | 83,385.33 | Form 4, filing 0000899243-23-013992 | |
| 2023-05-24 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 308,290 disposed | 6.57 | 2,023,985.51 | Form 4, filing 0000899243-23-013992 | |
| 2023-05-24 |
Sana Biotechnology, Inc. SANA |
S, Open-market sale | 39,580 disposed | 6.57 | 259,850.62 | Form 4, filing 0000899243-23-013992 | |
| 2022-09-15 |
Codiak BioSciences, Inc. CDAK |
P, Open-market purchase | 722,590 acquired | Not reported | Not priced | Form 4, filing 0000899243-22-031404 | |
| 2022-09-15 |
Codiak BioSciences, Inc. CDAK |
P, Open-market purchase | 210,743 acquired | Not reported | Not priced | Form 4, filing 0000899243-22-031404 | |
| 2021-08-03 |
Omega Therapeutics, Inc. OMGA |
P, Open-market purchase | 661,764 acquired | 17.00 | 11,249,988.00 | Form 4, filing 0000899243-21-031797 | |
| 2021-08-03 |
Omega Therapeutics, Inc. OMGA |
P, Open-market purchase | 294,117 acquired | 17.00 | 4,999,989.00 | Form 4, filing 0000899243-21-031797 | |
| 2021-08-03 |
Omega Therapeutics, Inc. OMGA |
P, Open-market purchase | 220,588 acquired | 17.00 | 3,749,996.00 | Form 4, filing 0000899243-21-031797 | |
| 2020-10-16 |
Codiak BioSciences, Inc. CDAK |
P, Open-market purchase | 165,000 acquired | 15.00 | 2,475,000.00 | Form 4, filing 0000899243-20-028807 | |
| 2018-05-11 |
Evelo Biosciences, Inc. EVLO |
P, Open-market purchase | 281,250 acquired | 16.00 | 4,500,000.00 | Form 4, filing 0000899243-18-013013 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Flagship V VentureLabs Rx Fund, L.P., insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001724939
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6